Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study
Year: 2026
Type: article
Abstract: The Orbit study confirmed safety and effectiveness of ibrutinib in Japanese patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This post-hoc analysis evaluated ibrutinib treatment patterns and impact of dose modifications, stratifying patients into three subgroups: (1) continuous full-dose (420 mg/day); (2) initially full-dose then discontinued and restarted; (3) reduced starting dose. Dose modifications after resumption in subgroup 2 were mainly due to adverse events (78.5%), and reduced starting doses in subgroup 3 were mainly due to adverse event concerns (79.7%). In subgroup 3, 89.2% experienced dose modification and 32.3% increased to 420 mg/day. Mean relative dose intensity was higher in subgroup 1 than 2/3 (92.5% vs 73.8%/48.1%). The 36-month progression-free survival (PFS)/overall survival rates were 67.9%/88.3%, 75.9%/89.2%, and 86.0%/86.5%, respectively. Subgroups 1 and 3 mainly included biologically unfavorable diseases and elderly vulnerable patients, respectively. Individualized ibrutinib dosing may be effective in maintaining CLL treatment even in real-world practice.
Authors: Yasushi Isobe, Tsuyoshi Muta, Yosuke Masamoto, Go Yamamoto, Shingo Kurahashi, Yoshihiro Kameoka, Shuichi Ota, Eri Matsuki, Kazutaka Ozeki, Takanori Toyama, Naoki Takahashi, Takahiro Kumode, Nobuyuki Aotsuka, Takuro Yoshimura, Hideto Tamura, Ai Omi, Kazuhiro Shibayama, Yuma Fujimori, Kensuke Kojima, Jun Takizawa, Hirokazu Nagai, Junji Suzumiya, Sadao Aoki
Institutions: Fukuoka University Hospital, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, University of Tokyo Hospital, Toranomon Hospital, Toyohashi Municipal Hospital, Akita University, Akita Red Cross Hospital, Sapporo Hokuyu Hospital, Keio University, Konan Kosei Hospital, Miyazaki Prefectural NOBEOKA Hospital, Saitama International Medical Center, Saitama Medical University, Kindai University Hospital, Japanese Red Cross Narita Hospital, Osaka City General Hospital, Dokkyo University, Dokkyo Medical University Saitama Medical Center, Nippon Medical School, Johnson & Johnson K.K. (Japan), University of Kochi, Kōchi University, Niigata University, Nagoya Medical Center, Niigata University of Pharmacy and Medical and Life Sciences
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7235403692
